Tag Archives: Endpoints news

Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.
大家好。我是《端点新闻》(Endpoints News)的发行人阿萨兰-阿里夫(Arsalan Arif),很高兴担任今天的主持人。今天的网络研讨会由澳大利亚 Agilex 生物实验室赞助。我们的主题是:为什么澳大利亚是世界领先的早期阶段目的地--快速启动、无需 IND 以及政府支持退还近一半的试验费用。今天我请来了两位嘉宾。他们分别是 Agilex Biolabs 公司免疫测定部总监库尔特-萨尔斯(Kurt Sales)和 CMAX 临床研究公司首席执行官简-凯利(Jane Kelly)。
为一项试验召集主要的临床服务供应商可能是一个令人生畏的过程--尤其是当您要到海外重新启动试验或开始新的试验以弥补 COVID 延误时更是如此。

然而,澳大利亚拥有一批久经考验的顶级供应商,他们定期合作,充分参与,并与流程、彼此的要求和能力保持一致,因此简化的流程令人耳目一新。这使得生物技术公司在澳大利亚开展试验的过程更加顺畅、专业和快速。本网络研讨会将探讨将试验转移到澳大利亚如何比您想象的要容易得多。
One of the most important drug development start-up decisions is finding a centrally located bioanalytical laboratory that can support clinical research across all the study locations, and through pre-clinical then potentially for all Phases.

Quality control and consistency of sample management and analysis from early Phase onwards can make a real difference to quality of data and final outcomes.